natgillin/translations-raw huggingface dataset:
If you take more Clopidogrel Acino Pharma than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding.
Če ste vzeli večji odmerek zdravila Klopidogrel Acino Pharma, kot bi smeli Zaradi povečanega tveganja krvavitve se posvetujte s svojim zdravnikom ali oddelkom najbližje bolnišnične nujne zdravniške pomoči.
Thrombolytics: the safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction.
Trombolitiki: varnost sočasne uporabe klopidogrela, fibrinsko specifičnih ali fibrinsko nespecifičnih trombolitikov in heparinov je bila ovrednotena pri bolnikih z akutnim miokardnim infarktom.
Because the active metabolite is formed by CYP450 enzymes, some of which are polymorphic or subject to inhibition by other medicinal products, not all patients will have adequate platelet inhibition.
Ker aktivni presnovek nastane z delovanjem encimov CYP450, od katerih so nekateri polimorfni ali podvrženi zavrtju z drugimi zdravili, se ustrezno zavrtje trombocitov ne pojavi pri vseh bolnikih.
By preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming (a process called thrombosis).
S preprečevanjem tega zlepljanja, zaviralci agregacije trombocitov zmanjšajo možnost nastanka krvnih strdkov (proces se imenuje tromboza).
It also contains hydrogenated castor oil.
SEZNAM POMOŽNIH SNOVI Vsebuje tudi hidrogenirano ricinusovo olje.
The usual dose is one 75 mg tablet of Clopidogrel Acino Pharma per day to be taken orally with or without food, and at the same time each day.
Običajni odmerek je ena 75-mg tableta zdravila Klopidogrel Acino Pharma na dan, ki jo lahko vzamete s hrano ali brez nje; odmerek morate jemati vsak dan ob istem času.
During non clinical studies in rat and baboon, the most frequently observed effects were liver changes.
V predkliničnih študijah na podganah in pavijanih, so bile jetrne spremembe najpogosteje opaženi učinek.
At steady state, the average inhibition level observed with a dose of 75 mg per day was between 40% and 60%.
V stanju dinamičnega ravnovesja je bila povprečno opažena raven zaviranja z odmerkom 75 mg na dan med 40 % in 60 %.
Due to the irreversible binding, platelets exposed are affected for the remainder of their lifespan (approximately 7 - 10 days) and recovery of normal platelet function occurs at a rate consistent with platelet turnover.
Zaradi ireverzibilne vezave se učinek na izpostavljene trombocite ohrani vso njihovo preostalo življenjsko dobo (približno 7-10 dni) in normalno delovanje trombocitov se obnovi s hitrostjo, ki je v skladu s premeno trombocitov.
The incidence of clinically significant bleeding was similar to that observed when thrombolytic agents and heparin are co-administered with ASA (see section 4.8)
Incidenca klinično pomembnih krvavitev je bila podobna tisti, ki so jo opazili pri uporabi trombolitikov in heparina sočasno z ASA (glejte poglavje 4.8).
The CYP2C19*2 and CYP2C19*3 alleles account for the majority of reduced function alleles in Caucasian (85%) and Asian (99%) poor metabolisers.
Na račun alelov CYP2C19*2 in CYP2C19*3 gre večina alelov z zmanjšanim delovanjem pri Kavkazijcih (85%) in pri Azijcih (99 %), ki so slabi metabolizatorji.
Patients were randomised to clopidogrel 75 mg/day or ASA 325 mg/day, and were followed for 1 to 3 years.
Bolniki so bili naključno razdeljeni v skupine, ki so prejemale klopidogrel 75 mg/dan ali ASA 325 mg/dan, spremljali so jih od 1 do 3 let.
Detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu/
DATUM ZADNJE REVIZIJE BESEDILA Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMA) http://www.ema.europa.eu/.
The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial infarction (< 35 days), recent ischaemic stroke (between 7 days and 6 months) or established peripheral arterial disease (PAD).
Študija CAPRIE je vključevala 19.185 bolnikov z aterotrombozo, ki se je odrazila z nedavnim miokardnim infarktom (< 35 dni), ishemično kapjo (med 7 dni in 6 meseci) ali razvito periferno arterijsko boleznijo (PAD).
Platelets (so-called thrombocytes) are very small structures, which clump together during blood clotting.
Trombociti so zelo majhne strukture, ki se zlepljajo pri strjevanju krvi.
There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers (except cimetidine which is a CYP2C19 inhibitor) or antacids interfere with antiplatelet activity of clopidogrel.
Ni dokazov, da druga zdravila za zmanjševanje želodčne kisline, npr. antagonisti histaminskih receptorjev H2 (razen cimetidina, ki je CYP2C19 inhibitor) ali antacidi, ovirajo antitrombocitno delovanje klopidogrela.
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR = -4.0%; CI: -22.5 to 11.7 [p=0.639]).
Pri bolnikih, ki so bili vključeni v preskušanje samo na podlagi nedavnega miokardnega infarkta, je bil klopidogrel numerično inferioren, vendar se statistično ni razlikoval od ASA (zmanjšanje RT= -4,0 %; IZ: -22,5 do 11,7 [p=0,639]).
Retroperitoneal haemorrhage
Retroperitonealna krvavitev
They are supplied in cardboard cartons containing 14, 28, 30, 50, 84, 90 and 100 tablets in aluminium blisters.
Na voljo so v škatlah, ki vsebujejo 14, 28, 30, 50, 84, 90 in 100 tablet v pretisnih omotih iz aluminija.
Clopidogrel has been tested in a range of in vitro and in vivo genotoxicity studies, and showed no genotoxic activity.
Klopidogrel so preizkušali v številnih in vitro ter in vivo študijah genotoksičnosti in ni pokazal nobenega genotoksičnega učinka.
Alu/Alu blisters containing 14, 28, 30, 50, 84, 90 and 100 film-coated tablets packed in cardboard cartons.
Alu/Alu pretisni omoti, ki vsebujejo 14, 28, 30, 50, 84, 90 in 100 filmsko obloženih tablet v kartonskih škatlah.
Like all medicines, Clopidogrel Acino Pharma can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Klopidogrel Acino Pharma neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
These occurred at doses representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day and were a consequence of an effect on hepatic metabolising enzymes.
Pojavile so se pri odmerkih, ki predstavljajo najmanj 25-kratno izpostavljenost kot pri človeku ob prejemanju kliničnega odmerka 75 mg/dan in so bile posledica učinka na jetrne presnovne encime.
Acetylsalicylic acid (ASA): ASA did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation, but clopidogrel potentiated the effect of ASA on collagen-induced platelet aggregation.
Acetilsalicilna kislina (ASA): ASA ni spremenila s klopidogrelom dosežene inhibicije z ADP-jem sprožene agregacije trombocitov, vendar klopidogrel ojača učinek ASA na s kolagenom sproženo agregacijo trombocitov.
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘POSSIBLE SIDE EFFECTS').
• morate takoj povedati zdravniku, če razvijete bolezensko stanje (znano tudi kot trombotična trombocitopenična purpura ali TTP) z zvišano telesno temperaturo in modricami pod kožo, ki se lahko pojavijo kot drobne rdeče pike, z ali brez nerazložljive hude utrujenosti, zmedenosti, porumenele kože ali oči (zlatenica) (glejte poglavje 4 »MOŽNI NEŽELENI UČINKI«).
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel Acino Pharma.
Če menite, da se karkoli od navedenega nanaša na vas, ali če ste kakorkoli v dvomih, se posvetujte s svojim zdravnikom, preden boste vzeli Klopidogrel Acino Pharma.
If you become pregnant while taking Clopidogrel Acino Pharma, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant.
Če med zdravljenjem z zdravilom Klopidogrel Acino Pharma zanosite, se takoj posvetujte s svojim zdravnikom, saj jemanje klopidogrela med nosečnostjo ni priporočljivo.
- For more than 12 hours: patients should take the next dose at the regular scheduled time and should not double the dose.
- če je zamuda več kot 12 ur: bolnik naj naslednji odmerek vzame ob pravem času; odmerka ne sme podvojiti.
Taking Clopidogrel Acino Pharma with food and drink Clopidogrel Acino Pharma may be taken with or without food.
Jemanje zdravila Klopidogrel Acino Pharma skupaj s hrano in pijačo Zdravilo Klopidogrel Acino Pharma lahko jemljete s hrano ali brez nje.
White to off-white, marbled, round and biconvex film-coated tablets.
Bele do belkaste, marmorirane, okrogle, bikonveksne filmsko obložene tablete.
If you forget to take a dose of Clopidogrel Acino Pharma, but remember within 12 hours of your usual time, take your tablet straight away and then take your next tablet at the usual time.
Če ste pozabili vzeti zdravilo Klopidogrel Acino Pharma Če pozabite vzeti odmerek zdravila Klopidogrel Acino Pharma in se nanj spomnite do 12 ur po ustaljenem času, takoj vzemite tableto in nato vzemite naslednjo tableto spet ob ustaljenem času jemanja.
It is characterised by thrombocytopenia and microangiopathic haemolytic anaemia associated with either neurological findings, renal dysfunction or fever.
Zanjo je značilna trombocitopenija in mikroangiopatična hemolitična anemija povezana bodisi z nevrološkimi spremembami, motnjo v delovanju ledvic ali vročino.
Other side effects reported with Clopidogrel Acino Pharma are: -Common side effects:
Drugi neželeni učinki, o katerih so poročali s Klopidogrel Acino Pharma, so: - Pogosti neželeni učinki:
In a small number of cases, bleeding in the eye, inside the head, the lung or the joints has also been reported.
V majhnem številu primerov so poročali tudi o očesnih krvavitvah, krvavitvah v glavi, pljučih ali sklepih.
Appropriate therapy should be considered if bleedings are observed.
V primeru krvavitev je potrebno zagotoviti ustrezno zdravljenje.
Acute liver failure, hepatitis, abnormal liver function test
Akutna odpoved jeter, hepatitis, nenormalni testi jetrne funkcije
Clopidogrel significantly reduced the incidence of new ischaemic events (combined end point of myocardial infarction, ischaemic stroke and vascular death) when compared to ASA.
Klopidogrel je pomembno zmanjšal incidenco novih ishemičnih dogodkov (sestavljen opazovani dogodek miokardni infarkt, ishemična kap in žilna smrt) v primerjavi z ASA.
Driving and using machines Clopidogrel Acino Pharma is unlikely to affect your ability to drive or to use machines.
Vpliv na sposobnost upravljanja vozil in strojev Ni verjetno, da bi zdravilo Klopidogrel Acino Pharma vplivalo na vašo sposobnost za vožnjo ali upravljanje strojev.
If you experience prolonged bleeding when taking Clopidogrel Acino Pharma.
Če doživite podaljšanje krvavitve v času jemanja zdravila Klopidogrel Acino Pharma.
Consequently, NSAIDs including Cox-2 inhibitors and clopidogrel should be co-administered with caution (see section 4.4).
Zaradi tega moramo NSAIDs, vključno s COX2 inhibitorji, in klopidogrel sočasno uporabljati previdno (glejte poglavje 4.4).
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel Acino Pharma.
Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti svojega zdravnika ali farmacevta, preden vzamete zdravilo Klopidogrel Acino Pharma.
Contact your doctor or pharmacist before stopping.
Posvetujte se s svojim zdravnikom ali farmacevtom, preden prekinete zdravljenje.
Co-administration of heparin had no effect on the inhibition of platelet aggregation induced by clopidogrel.
Sočasna uporaba heparina ni imela nobenega učinka na inhibicijo agregacije trombocitov, sprožene s klopidogrelom.
Clopidogrel Acino Pharma is taken to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death).
Zdravilo Klopidogrel Acino Pharma se jemlje za preprečevanje nastanka krvnih strdkov (trombov) v otrdelih krvnih žilah (arterijah), proces je znan kot aterotromboza in lahko vodi do aterotrombotičnih dogodkov (kot so kap, srčni napad ali smrt).
You should take Clopidogrel Acino Pharma for as long as your doctor continues to prescribe it.
Zdravilo Klopidogrel Acino Pharma morate jemati, vse dokler vam ga vaš zdravnik predpisuje.
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 4 ‘POSSIBLE SIDE EFFECTS').
Če pa vas glede krvavitve skrbi, se nemudoma posvetujte z zdravnikom (glejte poglavje 4 »MOŽNI NEŽELENI UČINKI«).
Musculo-skeletal bleeding (haemarthrosis), arthritis, arthralgia, myalgia
Mišično-skeletne krvavitve (hemartroza), artritis, artralgija, mialgija
Experience is limited in patients with moderate hepatic disease who may have bleeding diatheses.
Izkušnje so omejene pri populaciji z zmerno jetrno boleznijo, ki imajo lahko hemoragično diatezo.
If a dose is missed: - Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time.
Če bolnik izpusti odmerek: - če je zamuda manj kot 12 ur po pravem času: bolnik naj odmerek vzame takoj, potem pa naslednji odmerek ob pravem času.
No effect on hepatic metabolising enzymes was observed in humans receiving clopidogrel at the therapeutic dose.
Nobenega učinka na presnovne encime niso opazili pri ljudeh ob prejemanju terapevtskih odmerkov.
What Clopidogrel Acino Pharma is and what it is used for Before you take Clopidogrel Acino Pharma How to take Clopidogrel Acino Pharma Possible side effects
Kaj je zdravilo Klopidogrel Acino Pharma in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Klopidogrel Acino Pharma Kako jemati zdravilo Klopidogrel Acino Pharma Možni neželeni učinki
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p=0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event.
Pri analizi vključenih bolnikov (“intention to treat analysis”) so v skupini, ki je prejemala klopidogrel, opazili 939 dogodkov in v skupini, ki je prejemala ASA, 1.020 dogodkov (zmanjšanje relativnega tveganja (RT) 8,7 %, [95 % IZ: 0,2 do 16,4]; p=0,045), kar ustreza preprečevanju pojava novega ishemičnega dogodka na vsakih 1.000 bolnikov, zdravljenih 2 leti, dodatnim 10 [IZ: 0 do 20] bolnikom.
If you stop taking Clopidogrel Acino Pharma Do not stop the treatment unless your doctor tells you so..
Če ste prenehali jemati zdravilo Klopidogrel Acino Pharma Ne prekinite zdravljenjaa razen, če tako odloči zdravnik.
Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced by the coadministration of phenobarbital or oestrogen.
Poleg tega na farmakodinamično aktivnost klopidogrela ni pomembno vplivala sočasna uporaba fenobarbitala ali estrogena.
HOW TO STORE CLOPIDOGREL ACINO PHARMA Store in the original blister in order to protect from moisture.
SHRANJEVANJE ZDRAVILA KLOPIDOGREL ACINO PHARMA Shranjujte v originalnem pretisnem omotu za zagotovitev zaščite pred vlago.
Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4).
Zaviralci glikoproteina IIb/IIIa: klopidogrel moramo uporabljati previdno pri bolnikih, ki prejemajo sočasno zaviralce glikoproteina IIb/IIIa (glejte poglavje 4.4).
The incidence of severe cases was similar for clopidogrel and 1.6% for ASA.
Incidenca hujših primerov je bila podobna za klopidogrel in za ASA.
Taste disturbances
Motnje okusa
• Renal impairment Therapeutic experience is limited in patients with renal impairment (see section 4.4).
• Okvara ledvic Terapevtske izkušnje pri bolnikih z okvaro ledvic so omejene (glejte poglavje 4.4).
A pharmacodynamic interaction between clopidogrel and heparin is possible, leading to increased risk of bleeding.
Farmakodinamična interakcija med klopidogrelom in heparinom je možna in vodi do povečanega tveganja za krvavitev.
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p=0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to 18.7 [p=0.258]).
Pri analizi podskupin glede na vključitveni pogoj (miokardni infarkt, ishemična kap in periferna arterijska bolezen/PAD/) je videti najmočnejšo korist (doseganje statistične značilnosti pri p=0,003) pri bolnikih, vključenih zaradi PAD (zlasti pri tistih, ki so doživeli tudi miokardni infarkt) (zmanjšanje RT=23,7 %; IZ: 8,9 do 36,2), in šibkejšo (ni bila pomembno različna od ASA) pri bolnikih s kapjo (zmanjšanje RT=7,3 %; IZ: -5,7 do 18,7 [p=0,258]).
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or nonsteroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors.
Kot pri drugih antitrombotikih, moramo klopidogrel uporabljati previdno pri bolnikih s tveganjem za povečano krvavitev zaradi poškodbe, kirurškega posega ali drugih patoloških stanj in pri bolnikih, ki so na zdravljenju z ASA, heparinom, zaviralci glikoproteina IIb/IIIa ali nesteroidnimi protivnetnimi zdravili (NSAIDs) vključno z zaviralci COX-2.
signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 ‘Take special care with Clopidogrel Acino Pharma').
To so lahko znaki redkega zmanjšanja števila določenih krvnih celic, - znaki jetrnih težav, kot je porumenelost kože in/ali oči (zlatenica), ki so lahko, ali pa ne, povezani s krvavitvijo, ki se pojavi pod kožo kot drobne rdeče pike, in/ali zmedenostjo (glejte poglavje 2 »Bodite posebno pozorni pri jemanju zdravila Klopidogrel Acino Pharma«).
The dose of 0.2 mg/kg achieved the mean percent inhibition of 49.3% (5 µM ADP-induced platelet aggregation) which was comparable to that of adults taking Plavix 75 mg/day.
Odmerek 0,2 mg/kg je dosegel povprečno 49,3 % zavrtje (agregacija trombocitov povzročena s 5 µM ADP), primerljivo kot pri odraslih ob uporabi zdravila Plavix v odmerku 75 mg/dan.
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme), angioedema, rash erythematous, urticaria, eczema, lichen planus
Bulozen dermatitis (toksična epidermalna nekroliza, StevensJohnsonov sindrom, multiformni eritem), angioedem, eritematozen izpuščaj, urtikarija, ekcem, lihen planus
Pharmacogenetics: In patients who are poor CYP2C19 metabolisers, clopidogrel at recommended doses forms less of the active metabolite of clopidogrel has a smaller effect on platelet function.
Farmakogenetika: Pri bolnikih, ki so slabi metabolizatorji CYP2C19, med uporabo priporočenih odmerkov klopidogrela nastane manj aktivnega presnovka klopidogrela in ima manjši učinek na delovanje trombocitov.
swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin.
- otekanje ust ali bolezni kože, kot so izpuščaj, srbenje in mehurji na koži.
Blood and the lymphatic system disorders
Bolezni krvi in limfatičnega sistema
Intracranial bleeding (some cases were reported with fatal outcome), headache, paraesthesia, dizziness
Intrakranialna krvavitev (opisani so primeri s smrtnim izidom), glavobol, parestezije, omotica
Mean peak plasma levels of unchanged clopidogrel (approximately 2.2 - 2.5 ng/ml after a single 75 mg oral dose) occurred approximately 45 minutes after dosing.
Povprečna največja koncentracija nespremenjenega klopidogrela v plazmi (približno 2,2-2,5 ng/ml po enem 75-mg peroralnem odmerku) se je pojavila približno 45 minut po odmerjanju.
Store in the original blister in order to protect from moisture.
Shranjujte v originalnih pretisnih omotih za zagotovitev zaščite pred vlago.
Oral anticoagulants: the concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.4).
Peroralni antikoagulanti: sočasna uporaba klopidogrela s peroralnimi antikoagulanti ni priporočljiva, ker lahko poveča intenzivnost krvavitev (glejte poglavje 4.4).
A pharmacodynamic interaction between clopidogrel and acetylsalicylic acid is possible, leading to increased risk of bleeding.
Farmakodinamična interakcija med klopidogrelom in acetilsalicilno kislino je možna in vodi do povečanega tveganja za krvavitev.
NSAIDs: in a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss.
Nesteroidna protivnetna zdravila (NSAIDs; “Non-Steroidal Anti-Inflammatory Drugs”): v klinični študiji, izvedeni pri zdravih prostovoljcih, je sočasna uporaba klopidogrela in naproksena povečala okultno izgubo krvi iz prebavil.
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis
Krvavitve v dihalih (hemoptiza, pljučna krvavitev), bronhospazem, intersticijski pnevmonitis
Important information about some of the ingredients of Clopidogrel Acino Pharma: Clopidogrel Acino Pharma contains hydrogenated castor oil which may cause stomach upset or diarrhoea.
Pomembne informacije o nekaterih sestavinah zdravila Klopidogrel Acino Pharma Zdravilo Klopidogrel Acino Pharma vsebuje hidrogenirano ricinusovo olje, ki lahko povzroči želodčne motnje ali drisko.
Jaundice; severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions; swelling in the mouth; blisters of the skin; skin allergy; inflammation of the mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain; changes in the way things taste.
- Zelo redki neželeni učinki: zlatenica, huda bolečina v trebuhu z ali brez bolečine v hrbtu, zvišana telesna temperatura, težave pri dihanju, ki so včasih povezane s kašljem, splošne alergijske reakcije, oteklina v ustih, mehurji na koži, kožna alergija, vnetje v ustih (stomatitis), znižanje krvnega tlaka, zmedenost, halucinacije, bolečine v sklepih, bolečine v mišicah, motnje okusa.
WHAT CLOPIDOGREL ACINO PHARMA IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO KLOPIDOGREL ACINO PHARMA IN ZA KAJ GA UPORABLJAMO
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, granulocytopenia, anaemia
Trombotična trombocitopenična purpura (TTP) (glejte poglavje 4.4), aplastična anemija, pancitopenija, agranulocitoza, huda trombocitopenija, granulocitopenija, anemija
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 2 ‘Take special care with Clopidogrel Acino Pharma').
Vendar pa se morate takoj posvetovati s svojim zdravnikom, če ste glede krvavitve v kakršnihkoli dvomih (glejte poglavje 2 »Bodite posebno pozorni pri jemanju zdravila Klopidogrel Acino Pharma«).
Serum sickness, anaphylactoid reactions
Serumska bolezen, anafilaktoidne reakcije
INFORMATION IN BRAILLE Clopidogrel Acino Pharma 75 mg
PODATKI V BRAILLOVI PISAVI Klopidogrel Acino Pharma 75 mg